TickerGuard
Buy Day today: Poor (44) Weak market breadth · major macro event coming up
KROS

Keros Therapeutics Inc

Healthcare · Biotechnology

11.60$ -0.9% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement KROS
Line item 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
101.1% 173.5% 24.2% 4.5% 8.1% 539.7% 34.6% 0.6%
-1.1% -73.5% -24.2% 100.0% -8.1% 100.0% 100.0% 99.4%
101.1% 173.8% 1,354.4% 274.3% 436.3% 89,574.8% 4,891.0% 53.1%
15.8% 31.8% 511.9% 106.1% 137.6% 23,068.9% 1,148.0% 19.2%
113.2% 200.1% 1,842.1% 380.5% 573.9% 112,643.7% 6,039.0% 70.4%
-16.9% -105.6% -1,866.3% -280.5% -573.9% -112,543.7% -5,939.0% 28.9%
0.1% 0.1% 0.2% 0.0% 0.0% 0.0% 0.0%
-10.8% -123.4% -1,821.3% -282.3% -523.4% -101,319.2% -5,269.1% 37.7%
2.6% 0.1% -6.9% 10.0% 0.0% -136.4% 8.5% 2.0%
-13.4% -123.4% -1,814.4% -292.3% -523.4% -101,319.2% -5,277.5% 35.7%
-7.7% -118.9% -1,796.9% -280.4% -520.0% -100,779.5% -5,234.5% 38.3%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?